Primary Mitochondrial Disease
2
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2022
2023
2024
2025
2026
2027
OMEICOS TherapeuticsOMT-28
AblivaKL1333
Clinical Trials (2)
Total enrollment: 180 patients across 2 trials
OMT-28 in Patients With Primary Mitochondrial Disease (PMD) (PMD-OPTION)
Start: May 2023Est. completion: Jul 2025
Phase 2Completed
Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease
Start: Dec 2022Est. completion: Nov 2027180 patients
Phase 2Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 180 patients
2 companies competing in this space